Risks of leukaemia and solid tumours in individuals with Down's syndrome.
about
Down syndrome: searching for the genetic culpritsAcute lymphoblastic leukaemiaTrisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteinsAneuploidy: cells losing their balanceDown's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1Aneuploidy affects proliferation and spontaneous immortalization in mammalian cellsIdentification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumorsPotential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome BrainDown syndrome and leukemia: insights into leukemogenesis and translational targetsTargeting the Mitotic Catastrophe Signaling Pathway in CancerOxidative stress, thyroid dysfunction & Down syndromeMoyamoya Syndrome: A Window of Moyamoya DiseaseAcute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing EntitiesMetastatic mechanisms in follicular cell-derived thyroid cancerMyeloid leukemia in Down syndromeTransient Abnormal Myelopoiesis and AML in Down Syndrome: an UpdateThe RUNX genes: gain or loss of function in cancerIncreased Skin Tumor Incidence and Keratinocyte Hyper-Proliferation in a Mouse Model of Down SyndromeNovel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populationsDosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycleA very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries.Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell responseParadoxes in carcinogenesis: new opportunities for research directions.An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model.Clinical and genetic aspects of testicular germ cell tumours.Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q.Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia.Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.Cancer risk in persons with oral cleft--a population-based study of 8,093 cases.Childhood cancer risk in those with chromosomal and non-chromosomal congenital anomalies in Washington State: 1984-2013Breast screening guidelines should be adapted in Down's syndromeNFAT proteins: emerging roles in cancer progression.Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressorsMethotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia.Aneuploidy and skeletal health.Data-driven information retrieval in heterogeneous collections of transcriptomics data links SIM2s to malignant pleural mesothelioma.Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes.
P2860
Q22241596-9C435491-1AA0-4286-80D3-1B6E4FDF1376Q24602387-C3580436-53BE-43DC-9455-0E634EEE59A9Q24622025-5F3A4224-EA4F-4308-99E4-9CE111DB6283Q24654413-CC2D078E-AE38-4BA9-AE19-3C28348292F0Q24654657-7B44F56D-2F31-4D91-8C9E-5BACBA949D6EQ24657978-92AF35CF-DB28-4415-A58F-6461397C0585Q24681268-F4E92307-FC91-4735-AFF3-71ECD4F0AB75Q26765647-15F8A041-6893-41A5-81BE-8B9AFD12EBF1Q26770335-5BDB7D8E-FCA4-490D-AA51-51B62FB44871Q26778544-0BDD2C0E-5E17-4B37-821D-566A3C908EA9Q26782125-CE1B8B81-5C09-4995-A511-BA86363FEA9AQ26800801-0FAA14EF-976C-40BB-B9B0-5964C0C3086EQ26851821-39F939E7-D990-4805-9847-1DD727668BC0Q27005646-C20E38BD-FB2D-4617-AAC6-DE1370DD2345Q27027258-3D25A0EC-731B-47AF-A410-0715B98CE7EDQ28079980-0815951C-192D-4333-A255-324D56DA12F3Q28247901-3FA05FA1-50DB-4F31-B7B1-07128EC5B318Q28552259-CD8BE4A0-ECF4-46FE-ADBE-71BCB1649D0FQ28943485-037542F6-1A94-439A-9873-F492AF8FC090Q30579297-1F3D6831-6173-4D66-A74D-5C8360C35529Q30585618-60D0F483-64F6-45EF-92A7-020A72518282Q31155155-592C296D-D6F3-4CA8-92F7-5A568D731321Q33293460-194E4816-4AC6-4ACB-AA37-0005A281F351Q33307796-8B3085CF-68D8-462F-A35A-7656F26E7F66Q33347763-23CA026D-4F4F-4873-A500-4FC79B5E955CQ33379640-CDDA6825-8D07-4FE8-B1EC-4CBFEB957E96Q33586588-699C024C-010C-4B5E-91C2-39D3465E952DQ33615910-C7192BA7-DCAF-4532-98D9-AE353FDAADC7Q33698398-C6B48673-35AF-4EEF-A985-C5F7518DE3A3Q33717768-BA16AE0A-4BED-428E-8426-F24596D9D83DQ33729995-0E750510-A191-49BA-A3E7-13AC5402847BQ33778674-EC552623-F244-4295-98AF-AE4CB1386B70Q33810395-54F2F0ED-49D6-4538-85B5-3E181D44302BQ33837647-58131E2F-A61C-4BC0-9191-FDBB38FD833CQ33864448-EA385AEB-38DD-4DE2-9449-857A48CF97E7Q33952766-B823D040-974B-4D74-A108-017EBDB4A868Q33986195-90A29B12-D3B3-4EDE-AFA5-6260F84EE627Q34059928-518157D5-DDB7-4BE1-86A9-82AD64333858Q34080003-22B17643-686B-45A2-B05B-16A3675ECA9FQ34229190-CDA9944C-EE13-4F7C-BA87-FFF365F3F66C
P2860
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@ast
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@en
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@nl
type
label
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@ast
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@en
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@nl
prefLabel
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@ast
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@en
Risks of leukaemia and solid tumours in individuals with Down's syndrome.
@nl
P1433
P1476
Risks of leukaemia and solid tumours in individuals with Down's syndrome
@en
P2093
I H Clemmensen
M Mikkelsen
P304
P356
10.1016/S0140-6736(99)05264-2
P407
P50
P577
2000-01-01T00:00:00Z